Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT06609343 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.

Track this trial

Bupropion for Fatigue in End-stage Kidney Disease Patients on Hemodialysis

Study acronym: BRISK
StatusNot Yet Recruiting
PhasePhase 1/2
Started
View on ClinicalTrials.gov ↗

Record History

See every version on ClinicalTrials.gov ↗

  1. Start date: Jun 1, 2026 to Aug 24, 2026v8
  2. Start date: Feb 2, 2026 to Jun 1, 2026
    • Trial status: Recruiting to Not Yet Recruiting
    • Site details revised
    v7
  3. Primary completion date: Mar 2026 to Nov 30, 2026
    • Start date: Nov 18, 2025 to Feb 2, 2026
    • Study completion date: Nov 2026 to Jan 30, 2027
    v6
  4. Trial status: Not Yet Recruiting to Recruiting
    • Site details revised
    v5
  5. Primary completion date: Jun 2025 to Mar 2026v4 Show 4 more changesShow less
    • Start date: Oct 18, 2024 to Nov 18, 2025
    • Trial status: Recruiting to Not Yet Recruiting
    • Study completion date: Nov 2025 to Nov 2026
    • Site details revised
Show 2 earlier versionsHide 2 earlier versions
  1. Trial status: Not Yet Recruiting to Recruiting
    • Start date changed from estimate of Nov 2024 to Oct 18, 2024
    • Site details revised
    v3
  2. Study description expanded, about 15 wordsv2
  1. Study First Submitted
  • Stopped: an ongoing trial was terminated, suspended or withdrawn.
  • Notable: the trial’s plan changed such as a big move in its timeline or size, a new primary endpoint, sponsor or phase, or recruiting opened or resumed.
  • Minor: routine progress and housekeeping, such as sites added or enrollment closed.
Fatigue is the most common symptom reported by end-stage kidney disease patients on maintenance hemodialysis. Unfortunately, there currently is no medical management for this overwhelming feeling of tiredness. As a result, patients continue to suffer with poor quality of life and impaired daily activities. The purpose of this pilot trial is to find out if bupropion (a medicine commonly prescribed for stopping smoking, seasonal mood disorder, and depression) may help lessen fatigue in hemodialysis patients. In this study, hemodialysis participants will receive bupropion tablet orally three times a week during routine dialysis procedure for consecutive 8 weeks. Study participants will complete a battery of questionnaires to self-report fatigue, cognition, and quality of life. The study team will collect biological specimens. All these procedures will be performed at the dialysis clinic during routine dialysis procedure.
Trial Details
NCT Number NCT06609343
Lead Sponsor The University of Texas Health Science Center at San Antonio
Conditions
(from sponsor)		 End Stage Renal Disease, Fatigue
Related terms Fatigue, Kidney Failure, Chronic
Enrollment 16 participants
Start Date
Primary Completion (estimated)
Study Completion (estimated)
Updated on ClinicalTrials.gov